Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events.

CONCLUSION:: In our study population, patients treated with intravitreal bevacizumab were significantly more likely to experience stroke during 2 years after first injection.
PMID: 30618282 [PubMed - as supplied by publisher]

Source: European Journal of Ophthalmology - January 8, 2019 Category: Opthalmology Authors: Weinstein O, Abu Tailakh M, Lifshitz T, Novack V, Levy J Tags: Eur J Ophthalmol Source Type: research